Abrégé

A mixed extract from ivy leaves and Coptidis rhizome according to the present invention: reduces alveolar macrophage numbers and expression levels of inflammatory cytokines and chemokines, which are increased by chronic obstructive pulmonary disease, especially chronic obstructive pulmonary disease aggravated by fine dust or fine dust including sand dust in air; alleviates the submucosal extension and hemorrhage caused by the infiltration of inflammatory cells; and suppresses the activated NF-kB signaling pathway, thereby exhibiting an pharmaceutical effect of preventing or treating the disease. [Representative drawing] figure 4

Classes IPC  ?

• A61K 36/25 - Araliaceae (famille du ginseng), p. ex. lierre, aralia, schefflera ou tétrapanax
• A61K 36/718 - Coptis (Coptis chinensis)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention provides a novel prodrug of a mirabegron compound or pharmaceutically acceptable salts thereof, a pharmaceutical composition comprising same as an active ingredient, and a pharmaceutical use of same for treating or improving an overactive bladder disease.

Classes IPC  ?

• C07D 277/40 - Radicaux amino ou imino non substitués
• A61K 31/426 - 1,3-Thiazoles
• A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie

Abrégé

Provided are: a pharmaceutical composition for preventing and/or treating respiratory diseases, containing, as an active ingredient, an extract of mixed herbal medicines of at least two selected from the group consisting of Saururus chinensis, Chelidonium majus, Solanum nigrum, and Trichosanthes kirilowii; a method for preparing the same; and a method for preventing and/or treating respiratory diseases, the method comprising administering the herbal medicine extract.

Classes IPC  ?

• A61K 36/78 - Saururaceae (famille du saururus cernuus)
• A61K 36/66 - Papaveraceae (famille du pavot), p. ex. sanguinaire du Canada
• A61K 36/81 - Solanaceae (famille de la pomme de terre), p. ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
• A61K 36/428 - Trichosanthes

Abrégé

The present invention relates to a composition for relieving, suppressing, or treating chronic pain, the composition containing, as an active ingredient, a Gastrodia elata extract or a compound separated therefrom, and to a method for preparing the same. The Gastrodia elata extract according to the present invention can be used as a pharmaceutical composition or a functional food composition, which is useful to relieve, suppress, and treat a variety of chronic pain.

Classes IPC  ?

• A61K 36/8988 - Gastrodia
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Classes IPC  ?

• C07C 311/19 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique à un atome de carbone acyclique d'un radical hydrocarboné substitué par des groupes carboxyle
• C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 275/28 - Dérivés d'urée, c.-à-d. composés contenant l'un des groupes les atomes d'azote ne faisant pas partie de groupes nitro ou nitroso ayant des atomes d'azote de groupes urée liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
• C07C 311/08 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 311/29 - Sulfonamides, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène liés par des liaisons simples ayant l'atome de soufre d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 237/24 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons du squelette carboné
• C07D 213/82 - AmidesImides en position 3
• C07D 215/08 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle avec l'atome d'azote du cycle acylé
• C07D 217/06 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle contenant l'azoteAlkylène-bis-isoquinoléines avec l'atome d'azote du cycle acylé par des acides carboxyliques, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
• C07D 231/18 - Un atome d'oxygène ou de soufre
• C07D 333/34 - Atomes de soufre
• C07C 311/14 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons
• C07D 239/42 - Un atome d'azote
• C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 275/06 - Composés hétérocycliques contenant des cycles thiazole-1, 2 ou thiazole-1, 2 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques avec des hétéro-atomes liés directement à l'atome de soufre du cycle
• C07D 277/36 - Atomes de soufre
• C07D 209/08 - IndolesIndoles hydrogénés avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone de l'hétérocycle
• C07D 277/56 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• C07D 295/215 - Radicaux dérivés d'analogues azotés de l'acide carbonique
• C07D 213/70 - Atomes de soufre
• C07D 307/64 - Atomes de soufre

Abrégé

A composition for suppressing cough, removing sputum, preventing and/or treating a respiratory disease comprising an extract of Coptidis rhizoma or a combined extract of Coptidis rhizoma with ivy leaf as an active ingredient, and a method of suppressing cough, removing sputum, and/or preventing and/or treating respiratory disease using the composition, are provided.

Classes IPC  ?

• A61K 36/718 - Coptis (Coptis chinensis)
• A61K 36/25 - Araliaceae (famille du ginseng), p. ex. lierre, aralia, schefflera ou tétrapanax

Abrégé

The present invention relates to a novel compound having the ability to inhibit the 11β-HSD1 enzyme or to a pharmaceutically acceptable salt thereof, to a method for producing same, and to a pharmaceutical composition containing same as an active ingredient. The compound according to the present invention selectively inhibits the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and can thus be effectively used as a therapeutic agent for treating diseases caused by the excessive activity of 11β-HSD1, e.g. non-insulin dependent (type 2) diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and diseases and conditions brought on by the excessive activity of glucocorticoids.

Classes IPC  ?

• C07C 311/12 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant des cycles
• A61K 31/18 - Sulfamides
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

The present invention relates to sustained-release complex preparations for the treatment of diabetes with improved drug compliance and to a method for preparing same. More particularly, the present invention relates to sustained-release complex oral preparations for the treatment of diabetes, which comprise: a) an inner layer that includes Metformin or pharmaceutically acceptable salts thereof, sustained-release carriers and a pharmaceutically acceptable excipient; b) an intermediate layer that does not include drugs and that includes a water-soluble polymer; and c) an outer layer that includes sulfonylurea-based drugs and a control release formulation, wherein Carbomer is used as the sustained-release carriers. According to the present invention, complex preparations for the treatment of diabetes, comprising the inner layer including Metformin, the intermediate layer and the outer layer including sulfonylurea-based drugs, use Carbomer as the sustained-release carriers of the inner layer, thus exhibiting the same release pattern as that of Amaryl Mex which has been used in conventional complex preparations for the treatment of diabetes. Furthermore, the greater part of the sustained-release carriers is decomposed after 24 hours, thus avoiding gastrointestinal tract disorders. The weight of the inner layer is minimized to reduce the size of a tablet to allow for ease of medicine taking, thus improving drug compliance of a patient.

Classes IPC  ?

• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

A composition for suppressing cough, removing sputum, preventing and/or treating a respiratory disease comprising an extract of Coptidis rhizoma or a combined extract of Coptidis rhizoma with ivy leaf as an active ingredient, and a method of suppressing cough, removing sputum, and/or preventing and/or treating respiratory disease using the composition, are provided.

Classes IPC  ?

• A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
• A61K 36/718 - Coptis (Coptis chinensis)
• A61K 36/25 - Araliaceae (famille du ginseng), p. ex. lierre, aralia, schefflera ou tétrapanax

Abrégé

The present invention relates to a controlled release type tablet containing aceclofenac. Particularly, the tablet has a multi-layer structure including a fast releasing layer and a slow releasing layer adjacent to each other. The slow releasing layer includes hydrophilic polymer, hypromellose and polyethylene oxide as slow releasing materials. While the tablet according to the present invention has an even smaller size than that of a conventional controlled release type tablet, it is designed for possible once-a-day dosage.

Classes IPC  ?

• A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate

Abrégé

The present invention relates to a mixed strain culture for the disposal of food waste, and more particularly, to a mixed strain culture for the disposal of food waste which has high degradation activity on cellulose, amylose, protein, and fat at a wide range of temperatures, pH levels, and salinities, and which can degrade food waste having a high moisture content and therefore can degrade food waste in an efficient manner. The present invention also relates to a food waste disposal method using the mixed strain culture.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• B09B 3/00 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif

Abrégé

A use an extract of Coptidis Rhizoma or a combined extract of Coptidis Rhizoma and Pharbitidis Semen as an active ingredient for preventing and/or treating periodontal disease is provided. The extract of Coptidis Rhizoma or a combined extract of Coptidis Rhizoma and Pharbitidis Semen has activities to stimulate anti-inflammation, osteoblast differentiation and alveolar bone regeneration, and to prevent the alveolar bone destruction, thereby being effective for the prevention and/or treatment of periodontal disease.

Classes IPC  ?

• A61K 36/718 - Coptis (Coptis chinensis)
• A61K 36/39 - Convolvulaceae (famille de la belle-de-jour), p. ex. liseron
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
• A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;

Abrégé

Coptidis rhizoma with ivy leaf as an active ingredient, and a method of suppressing cough, removing sputum, and/or preventing and/or treating respiratory disease using the composition, are provided.

Classes IPC  ?

• A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes

Abrégé

The present invention relates to a novel use of herbal extracts in a pharmaceutical composition for preventing and treating nephritis. More specifically, the present invention provides: a pharmaceutical composition and health food for preventing and/or treating nephritis containing one or more herbal extracts selected from the group consisting of Crataegus oxyacantha, Cinnamomum cassia Blume, Prunella vulgaris and Equiseti Herba; a method for treating nephritis using the herbal extracts; and a use of the herbal extracts for manufacturing a composition for preventing and/or treating nephritis. The herbal extracts are useful in preventing and/or treating nephritis in drug-induced nephritis models such as those induced by gentamicin, cisplatin and the like, and have a high suppression activity for mesangial cell growth in the kidney.

Classes IPC  ?

• A61K 36/73 - Rosaceae (famille de la rose), p. ex. fraise, aronia, mûre ou pyracantha
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61K 36/54 - Lauraceae (famille du laurier), p. ex. cannelle ou sassafras
• A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;

Abrégé

The embodiment proposes a method for preparing (S)-(-)- ethyl methyl 4-(2,3-dichlorophenyl)- 1,4-dihydro-2,6-dimethyl-3,5-pyridine- dicarboxylate (hereinafter, referring to as "(S)-(-)-felodipine", and more particularly, a method for effectively preparing the (S)-(-)-felodipine through a selective transesterification of -hydroxy ester after synthesizing a felodipine derivate including a chiral separation compound and isolating (S)-isomers. The chiral separation compound is synthesized from (R)-glycidol or (S)-glycidol through reaction with various nucleophiles and epoxide.

Classes IPC  ?

• C07D 211/90 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• C07D 213/80 - AcidesEsters en position 3

Abrégé

A composition for suppressing cough, removing sputum, preventing and/or treating a respiratory disease comprising an extract of Coptidis rhizoma or a combined extract of Coptidis rhizoma with ivy leaf as an active ingredient, and a method of suppressing cough, removing sputum, and/or preventing and/or treating respiratory disease using the composition, are provided.

Classes IPC  ?

• A61K 36/718 - Coptis (Coptis chinensis)
• A61K 36/25 - Araliaceae (famille du ginseng), p. ex. lierre, aralia, schefflera ou tétrapanax

Abrégé

The present invention relates to a process for the preparation of chiral 2-hydroxymethyl-l,4-benzodioxane compound. The method in accordance with the present invention comprises the steps of reacting chiral epihalohydrin or chiral glycidyl sulfonate with catechol or its derivative in a presence of a tertiary organic amine or its ammonium salt to carry out an ring opening reaction of the epoxide compound and treating the ring-opened product with an inorganic base to carry out a cyclization reaction of the ring-opened product to prepare the targeted 2-hydroxymethyl-l,4-benzodioxane. The method of the present invention provides the chiral 2-hydroxymethyl-l,4-benzodioxane compound in high optical purity and with improved yield due to reduced side reactions.

Classes IPC  ?

• C07D 319/20 - Dioxanes-1, 4Dioxanes-1, 4 hydrogénés condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle à six chaînons avec des substituants liés à l'hétérocycle

Abrégé

The present invention relates to a process for the efficient preparation of highly optical pure chiral carvedilol. According to the present invention, a chiral oxazolidin-2-one or oxazolidin-2-thione having formula 2, produced from the reaction of N-protected 2-(2-methoxyphenoxy)ethylamine with a chiral glycidol derivative is used as a key intermediate for the preparation of the chiral carvedilol. Specifically, the process for the preparation of the chiral carvedilol comprises a) reacting a compound of formula 2 with a halogenation agent, a sulfonation agent or a mitsunobu reagent to activate a hydroxyl group of the compound of formula 2, followed by nucleophilic substitution reaction with 9H-4-hydroxy carbazole to produce a compound of formula 7, and b) subjecting the obtained compound of formula 7 to a deprotection reaction in a presence of an inorganic base to produce the targeted chiral carvedilol. The process of the present invention can be accomplished in a mild condition. The process neither requires any extraordinary purification procedure, nor involves decrease of optical purity. Therefore, the process of the present invention provides highly optical pure chiral carvedilol in simple and efficient manner.

Classes IPC  ?

• C07D 209/88 - CarbazolesCarbazoles hydrogénés avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du système cyclique

Produits et services

Medical products affecting metabolism; vitamin preparations; medical products affecting digestive organs; cardiovascular medical products; medical products for ophthalmic use; antiallergic medical products; medical products affecting central nervous system; antibiotic preparations; medical products for respiratory organs; chemotherapy medicines.